C14-490
C14-490 is an ionizable cationic lipid used for the formulation of lipid nanoparticles (LNPs) for mRNA delivery. C14-490 LNPs can be surface-functionalized with CD45 antibodies to enable targeted delivery to hematopoietic stem cells (HSCs), mediate efficient mRNA delivery and CRISPR-Cas9 gene editing in fetal HSCs in utero, with potent and durable genome modulation in HSCs and their progeny. C14-490 is a key component of the Systematically optimized Targeted Editing Machinery (STEM) LNPs for in vivo HSC gene editing applications.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2639634-82-3
- Formule: C86H177N5O7
- Masse moléculaire:1393.35
-
Stockage:
Solution, -20°C, 2 years
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
C14-490 LNPs CD45 antibody conjugation to C14-490 LNPs increases average particle diameter by ~20 nm without altering PDI or mRNA encapsulation efficiency[1].
C14-490 LNPs conjugated to CD45 antibody (100 ng total mRNA, 24 h incubation) boost GFP mRNA delivery efficiency eightfold in Jurkat cells; 24 h administration of 100 ng mRNA leads to 35% GFP+ cells with no decline in cell viability[1].
C14-490 LNPs conjugated to CD45 antibody (25-150 ng total mRNA; 24 h) exhibit dose-dependent improvement in mRNA delivery to Jurkat cells, with maximum 10-fold enhancement at 50 ng mRNA per 30,000 cells after 24 h incubation[1].
C14-490 LNPs conjugated to CD45 antibody (100 ng total mRNA for Jurkat cells, 25 ng total mRNA for HepG2 cells; 24 h transfection, 30 min antibody pre-incubation) have enhanced mRNA delivery efficacy that is CD45 receptor-specific, as pre-treatment with free CD45 antibodies blocks the effect, and no enhancement is observed in CD45-negative HepG2 cells[1].
C14-490 ionizable lipid formulated into LNPs exhibit consistent size, low polydispersity, and high encapsulation efficiency[1].
C14-490 ionizable lipid in LNPs correlates with enhanced relative GFP knockout efficacy in HepG2-GFP cells, with a positive correlation coefficient of +0.34[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
14C-490 LNPs adopting optimized B5 formulation (1 mg/kg mRNA; i.v.; single in utero injection at E13.5) achieve higher intrauterine TTR locus gene editing efficiency in fetal liver than the unmodified A0 formulation[1].
14C-490 LNPs adopting optimized B5 formulation (1 mg/kg mRNA, i.v., single in utero injection at E13.5) yield fourfold enhanced TTR locus gene editing in fetal mouse HSCs compared with non-targeted B5-formulated counterparts post in utero injection[1]
C14-490 LNPs (1 mg/kg; in utero i.v.; single dose) drive robust GFP expression in fetal mouse hepatocytes, with minimal expression in fetal hematopoietic stem cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:R26mT/mG (B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J) mice (fetal, gestational day 13.5)[1]
-
Dosage:1 mg/kg mRNA
-
Administration:i.v.; single in utero injection at E13.5
-
Result:Mediated 50% transfection of fetal hepatocytes and 2% transfection of fetal HSCs (Lin-/Sca1+/cKit+).
Mediated 50% transfection of adult hepatocytes and no detectable genome modulation in adult bone marrow HSCs.
-
Animal Model:BALB/c mice (fetal, gestational day 13.5)[1]
-
Dosage:1 mg/kg total mRNA
-
Administration:i.v.; single in utero injection at E13.5
-
Result:Mediated threefold greater indels at the TTR locus in fetal liver tissue compared to unoptimized A0 C14-490 LNPs.\nMediated ~6% indels at the TTR locus in whole fetal liver tissue for both STEM and untargeted B5 formulations.
Mediated ~8% indels in fetal HSCs, which was fourfold higher than the ~2% indels mediated by untargeted B5 LNPs in fetal HSCs.
-
Animal Model:R26mT/mG (E13.5 fetuses, in utero model)[1]
-
Dosage:1 mg/kg
-
Administration:in utero i.v.; single dose
-
Result:Achieved a mean GFP+ percentage of 53% in fetal hepatocytes (CD45-/CD31-).
Showed non-significant mean GFP+ percentage in fetal hematopoietic stem cells (Lin-/Sca1+/cKit+).
Displayed widespread GFP fluorescence across whole fetuses and dissected fetal liver tissue via stereomicroscopy.
Chemical Information
-
CAS No. 2639634-82-3
-
Appearance Liquid
-
Masse moléculaire 1393.35
-
Formule C86H177N5O7
-
Color Colorless to light yellow
-
SMILES
OC(CCCCCCCCCCCC)CN(CC(CN(CC(CCCCCCCCCCCC)O)CC(CCCCCCCCCCCC)O)OCC)CCN1CCN(CC(CN(CC(CCCCCCCCCCCC)O)CC(CCCCCCCCCCCC)O)OCC)CC1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Solution, -20°C, 2 years
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
C14-490 Related Classifications
HY-165604 Related Classifications
Powered by Bioz